Submitting a Monograph
Guidelines for Homeopathic Drug Provings
Approved April 2015
Table Of Contents
- FOREWORD
- PERSONNEL QUALIFICATIONS & TRAINING
- Principal Investigator
- Project Coordinator / Administrator
- Proving Subject Supervisors
- Ethics Training
- INVESTIGATIONAL PROVING SUBSTANCE
- Investigational Proving Substance Manufacturer Information
- Identity of IPS
- IPS Manufacturing Process
- Toxicology
- Prior Clinical Information
- Prior Proving of the IPS
- DESIGN / METHODS
- Overall Study Design and Plan
- Controls
- Selection of Study Population
- Inclusion / Exclusion Criteria
- IPS Characteristics
- Randomization
- Dosing Frequency
- Criteria for Non-Repetition of Dose
- Blinding
- Therapeutic Intervention during Proving
- Number of Subjects / Sample Size
- Supervisor and Subject Interaction
- Definitions to be Included in Proving Timeline
- Follow-up period
- DATA COLLECTION AND RECORD KEEPING
- Data Labeling
- Data Management
- Subject Diary
- Supervisor / Principal Investigator Inputs
- SAFETY ASSURANCE
- Adverse Events
- Serious Adverse Events
- Single Subject Un-blinding in Connection with Adverse Events
- Individual Subject Discontinuation from Proving
- Event Handling Flow Chart
- DATA ANALYSIS
- Proving Symptoms
- Relative Characterizing Features
- Characteristic Symptoms
- Clinical Synopsis of the IPS
- Use of Control Results
- LEGAL / ETHICS
- Ethics or Institutional Review Board
- Informed Consent
- Subject Withdrawal Criteria
- Insurance coverage
- Financial Disclosure Certification
- MONOGRAPH REPORT
- Proving Report
- Monograph Report Submission Process
- APPENDIX A
- GLOSSARY